

A Reliable Research Partner in Life Science and Medicine

Recombinant Human VCAM-1/CD106 Protein (His Tag)

Catalog Number: PDMH100409

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Species Human

Source HEK293 Cells-derived Human VCAM-1 protein Phe25-Glu698, with an C-terminal

His

 Calculated MW
 76.7 kDa

 Observed MW
 100 kDa

 Accession
 P19320

Bio-activity Not validated for activity

Properties

Purity > 90% as determined by reducing SDS-PAGE.

Endotoxin < 1.0 EU/mg of the protein as determined by the LAL method

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -

80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

Shipping This product is provided as lyophilized powder which is shipped with ice packs.


Formulation Lyophilized from a 0.2 µm filtered solution in PBS with 5% Trehalose and 5%

Mannitol.

Reconstitution It is recommended that sterile water be added to the vial to prepare a stock solution

of 0.5 mg/mL. Concentration is measured by UV-Vis.

Data



SDS-PAGE analysis of Human VCAM-1/CD106 proteins, 2 µg/lane of Recombinant Human VCAM-1/CD106 proteins was resolved with SDS-PAGE under reducing conditions, showing bands at 100 kDa.

Background

For Research Use Only

 Toll-free: 1-888-852-8623
 Tel: 1-832-243-6086
 Fax: 1-832-243-6017

 Web: www.elabscience.com
 Email: techsupport@elabscience.com

Elabscience®

Elabscience Bionovation Inc.

A Reliable Research Partner in Life Science and Medicine

VCAM-1 is a single-pass type I membrane protein, contains 7 Ig-like C2-type domains. It is an endothelial ligand for very late antigen-4 (VLA-4) and $\alpha4\beta7$ integrin expressed on leukocytes, and thus mediates leukocyte-endothelial cell adhesion and signal transduction. VCAM-1 expression is induced on endothelial cells during inflammatory bowel disease, atherosclerosis, allograft rejection, infection, and asthmatic responses. During these responses, VCAM-1 forms a scaffold for leukocyte migration. VCAM-1 also activates signals within endothelial cells resulting in the opening of an "endothelial cell gate" through which leukocytes migrate. VCAM-1 has been identified as a potential ant i-inflammatory therapeutic target, the hypothesis being that reduced expression of VCAM-1 will slow the development of atherosclerosis. In addition, VCAM-1-activated signals in endothelial cells are regulated by cytokines indicating that it is important to consider both endothelial cell adhesion molecule expression and function during inflammatory processes.

For Research Use Only

 Toll-free: 1-888-852-8623
 Tel: 1-832-243-6086
 Fax: 1-832-243-6017

 Web: www.elabscience.com
 Email: techsupport@elabscience.com